
PRODUCT CLASSIFICATION
产品分类TECHNICAL ARTICLES
相关文章产品展示/ Product display
您的位置:首页 / 产品展示 / / CAR T-Cell Therapy Cell Lines / 79854Anti-CD19 CAR Negative Control/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 Transm...

产品型号:79854
厂商性质:生产厂家
更新时间:2023-11-11
访 问 量:381
立即咨询
联系电话:
Anti-CD19 CAR Negative Control/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 Transmembrane Motif) is a stable cell line expressing an anti-CD19 CAR negative control and an NFAT-dependent luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without the intracellular signaling domains. The reporter cell line has been validated for anti-CD19 expression by flow cytometry, and in co-culture with target cells, such as CD19/CHO recombinant cell line the luciferase reporter gene was not activated. Anti-CD19 CAR Negative Control Jurkat/NFAT (Luciferase) Reporter Cell Line was generated by the transduction of NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) with anti-CD19 CAR negative control lentivirus.
The cell line can be used as negative control for the Anti-CD19 CAR/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1-BB-CD3ζ) (BPS Bioscience #79853).

Figure 1: Lenti-vector used to generate anti-CD19 CAR negative control lentivirus.

Figure 2. Schematic of anti-CD19 CAR negative control.
The anti-CD19 (scFv) is linked to the CD28 transmembrane motif.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.